T cell-based immunotherapy of metastatic renal cell carcinoma: Modest success and future perspective

Alaaeldin Shablak, Robert E. Hawkins, Dominic G. Rothwell, Eyad Elkord

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

Metastatic renal cell carcinoma (MRCC) remains a challenging malignancy to treat. Cancer immunotherapies have been extensively explored in melanoma and RCC as they poorly respond to conventional cytotoxic agents but show responses to a variety of immunologic agents. The recent considerable success of T cell-based immunotherapy in melanoma warrants further efforts to apply this treatment to other cancers including MRCC. Although RCC is an immunosensitive cancer, similar attempts in MRCC have shown a very limited success. In this review, we summarize the clinical data on T cell-based immunotherapies for MRCC showing the modest success that has been achieved to date. More importantly, we discuss potential strategies for improving its efficacy for the treatment of MRCC in light of the important achievements for treating metastatic melanoma. In particular, the growing evidence of success by combining expanded tumor-infiltrating lymphocytes with lymphodepletion merits investigation in MRCC. Identifying new RCC-associated antigens, optimized methods, and conditions for detection, isolation, and/or modification and expansion of tumor-specific T cells are all important strategies to be pursued for improving T cell-based immunotherapy of MRCC.

Original languageEnglish
Pages (from-to)6503-6510
Number of pages8
JournalClinical Cancer Research
Volume15
Issue number21
DOIs
Publication statusPublished - 1 Nov 2009
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Immunotherapy
T-Lymphocytes
Melanoma
Neoplasms
Tumor-Infiltrating Lymphocytes
Cytotoxins
Antigens

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

T cell-based immunotherapy of metastatic renal cell carcinoma : Modest success and future perspective. / Shablak, Alaaeldin; Hawkins, Robert E.; Rothwell, Dominic G.; Elkord, Eyad.

In: Clinical Cancer Research, Vol. 15, No. 21, 01.11.2009, p. 6503-6510.

Research output: Contribution to journalReview article

Shablak, Alaaeldin ; Hawkins, Robert E. ; Rothwell, Dominic G. ; Elkord, Eyad. / T cell-based immunotherapy of metastatic renal cell carcinoma : Modest success and future perspective. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 21. pp. 6503-6510.
@article{81ae1576a0744b448f9974641644a485,
title = "T cell-based immunotherapy of metastatic renal cell carcinoma: Modest success and future perspective",
abstract = "Metastatic renal cell carcinoma (MRCC) remains a challenging malignancy to treat. Cancer immunotherapies have been extensively explored in melanoma and RCC as they poorly respond to conventional cytotoxic agents but show responses to a variety of immunologic agents. The recent considerable success of T cell-based immunotherapy in melanoma warrants further efforts to apply this treatment to other cancers including MRCC. Although RCC is an immunosensitive cancer, similar attempts in MRCC have shown a very limited success. In this review, we summarize the clinical data on T cell-based immunotherapies for MRCC showing the modest success that has been achieved to date. More importantly, we discuss potential strategies for improving its efficacy for the treatment of MRCC in light of the important achievements for treating metastatic melanoma. In particular, the growing evidence of success by combining expanded tumor-infiltrating lymphocytes with lymphodepletion merits investigation in MRCC. Identifying new RCC-associated antigens, optimized methods, and conditions for detection, isolation, and/or modification and expansion of tumor-specific T cells are all important strategies to be pursued for improving T cell-based immunotherapy of MRCC.",
author = "Alaaeldin Shablak and Hawkins, {Robert E.} and Rothwell, {Dominic G.} and Eyad Elkord",
year = "2009",
month = "11",
day = "1",
doi = "10.1158/1078-0432.CCR-09-1605",
language = "English",
volume = "15",
pages = "6503--6510",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - T cell-based immunotherapy of metastatic renal cell carcinoma

T2 - Modest success and future perspective

AU - Shablak, Alaaeldin

AU - Hawkins, Robert E.

AU - Rothwell, Dominic G.

AU - Elkord, Eyad

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Metastatic renal cell carcinoma (MRCC) remains a challenging malignancy to treat. Cancer immunotherapies have been extensively explored in melanoma and RCC as they poorly respond to conventional cytotoxic agents but show responses to a variety of immunologic agents. The recent considerable success of T cell-based immunotherapy in melanoma warrants further efforts to apply this treatment to other cancers including MRCC. Although RCC is an immunosensitive cancer, similar attempts in MRCC have shown a very limited success. In this review, we summarize the clinical data on T cell-based immunotherapies for MRCC showing the modest success that has been achieved to date. More importantly, we discuss potential strategies for improving its efficacy for the treatment of MRCC in light of the important achievements for treating metastatic melanoma. In particular, the growing evidence of success by combining expanded tumor-infiltrating lymphocytes with lymphodepletion merits investigation in MRCC. Identifying new RCC-associated antigens, optimized methods, and conditions for detection, isolation, and/or modification and expansion of tumor-specific T cells are all important strategies to be pursued for improving T cell-based immunotherapy of MRCC.

AB - Metastatic renal cell carcinoma (MRCC) remains a challenging malignancy to treat. Cancer immunotherapies have been extensively explored in melanoma and RCC as they poorly respond to conventional cytotoxic agents but show responses to a variety of immunologic agents. The recent considerable success of T cell-based immunotherapy in melanoma warrants further efforts to apply this treatment to other cancers including MRCC. Although RCC is an immunosensitive cancer, similar attempts in MRCC have shown a very limited success. In this review, we summarize the clinical data on T cell-based immunotherapies for MRCC showing the modest success that has been achieved to date. More importantly, we discuss potential strategies for improving its efficacy for the treatment of MRCC in light of the important achievements for treating metastatic melanoma. In particular, the growing evidence of success by combining expanded tumor-infiltrating lymphocytes with lymphodepletion merits investigation in MRCC. Identifying new RCC-associated antigens, optimized methods, and conditions for detection, isolation, and/or modification and expansion of tumor-specific T cells are all important strategies to be pursued for improving T cell-based immunotherapy of MRCC.

UR - http://www.scopus.com/inward/record.url?scp=70350716447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350716447&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-1605

DO - 10.1158/1078-0432.CCR-09-1605

M3 - Review article

C2 - 19843660

AN - SCOPUS:70350716447

VL - 15

SP - 6503

EP - 6510

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 21

ER -